JNJ

For questions about this article or underlying research, email help@trefis.com.

Key Stats for Johnson & Johnson StockCurrent Price: $273. 20Target Price (Mid): ~$342Street Target: ~$279Potential Total Return: ~25%Annualized IRR: ~5.

ETFs bought $35.1 million of Johnson & Johnson stock on Oct. 29.

Johnson & Johnson's Innovative Medicine segment outperforms, driven by Darzalex, Tremfya, and promising pipeline drugs. See why I rate JNJ stock a Hold.

Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Johnson & Johnson has released a string of positive trial readouts and product updates in oncology, immunology and MedTech, including data for subcutaneous amivantamab, JNJ-6143 and TREMFYA, alongside new device launches and regulatory…

Merck and Eli Lilly both beat Wall Street, but their paths to profit look nothing alike, and the gap between them could widen sharply as one faces a looming patent cliff and the other rides an unstoppable drug category.

Johnson & Johnson's Q3 results showed the strength of the pharma business. Click here to read more about JNJ stock and why it is rated a Hold.

Johnson & Johnson has delivered strong share gains in recent years, so the key issue now is whether the current valuation is properly backed by the cash the business is expected to generate.

NEW BRUNSWICK, N.J., October 27, 2026--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026.